DiaMedica Therapeutics (DMAC) Change in Acquisitions & Divestments (2019 - 2026)

DiaMedica Therapeutics (DMAC) has reported Change in Acquisitions & Divestments for 8 consecutive years, with $13.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Acquisitions & Divestments fell 29.6% year-over-year to $13.0 million; the trailing twelve-month figure through Jun 2026 stood at $54.9 million (down 14.1% YoY), and the FY2025 full-year result was $57.1 million, down 3.18% from the prior year.
• Change in Acquisitions & Divestments slipped to $13.0 million in Q2 2026 per DMAC's latest filing, from $16.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $18.5 million in Q2 2025 and bottomed at $9.1 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $14.1 million across 5 years, with a median of $14.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments surged 45.45% in 2024, then plunged 43.1% in 2025.
• Over 5 years, Change in Acquisitions & Divestments stood at $14.5 million in 2022, then decreased by 24.37% to $11.0 million in 2023, then soared by 45.45% to $16.0 million in 2024, then grew by 0.34% to $16.1 million in 2025, then slipped by 19.03% to $13.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $13.0 million, $16.8 million, and $16.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.